CYB5R3 (F1D9O) Rabbit mAb #84402
- WB
- IF
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 28 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunofluorescence (Frozen) | 1:50 - 1:200 |
| Immunofluorescence (Immunocytochemistry) | 1:100 - 1:400 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
Mutations in the CYB5R3 gene can lead to both Type I and Type II methemoglobinemia, a rare genetic disorder characterized by elevated levels of methemoglobin in the blood, leading to chronic cyanosis and neurological dysfunction (3,4). Downregulation of CYB5R3 has been shown to promote tumorigenesis and lung metastasis in mouse models whereas overexpression can induce ER stress-mediated apoptosis, thus implicating CYB5R3 as a tumor suppressor (5). Additionally, CYB5R3 is essential for cardiomyocyte function and may have critical protective effects on vascular function and sudden cardiac death (6,7).
- Elahian, F. et al. (2014) Crit Rev Biotechnol 34, 134-43.
- Ishimura, R. et al. (2022) Nat Commun 13, 7857.
- Percy, M.J. and Lappin, T.R. (2008) Br J Haematol 141, 298-308.
- Fermo, E. et al. (2008) Blood Cells Mol Dis 41, 50-5.
- Im, J.Y. et al. (2024) Exp Mol Med 56, 235-249.
- Durgin, B.G. et al. (2022) J Mol Cell Cardiol 162, 72-80.
- Carew, N.T. et al. (2022) J Clin Invest 132, e147120. doi: 10.1172/JCI147120.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.